MAPK1 and type 2 diabetes mellitus: Further, our findings propose that AKT1, MAPK3, TNFalpha, and MAPK1 genes are promising and viable therapeutic targets to reduce the incidence of T2DM, thereby exerting potential therapeutic effects in T2DM.